Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Treatment of Crohn’s disease with anti-IL-6 receptor antibody

Abstract

We have demonstrated, by using a T-cell transfer murine colitis model, that blocking interleukin 6 (IL-6) signaling with monoclonal antibody (mAb) to IL-6 receptor (IL-6R) abrogated apoptosis resistance of lamina propria T cells, suppressed the expression of vascular adhesion molecules, and successfully prevented and treated intestinal inflammation. Based on these results, we carried out an exploratory clinical trial to investigate the safety and efficacy of humanized anti-IL-6R mAb, MRA, in patients with Crohn’s disease (CD). The results were promising, with 80% of the patients given every-2-week MRA infusions for 12 weeks showing a significantly higher clinical response rate as compared to 31% of the placebo-treated patients. Twenty percent of the patients on this regimen went into remission as compared to 0% of the placebo group. The acute-phase responses were normalized by a single MRA infusion, which strongly suggests IL-6 is the major cytokine responsible for their production in CD.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36: 45–9.

  2. 2.

    Hosokawa T, Kusugami K, Ina K, Ando T, Shinoda M, Imada A, et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999; 14: 987–96.

  3. 3.

    Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001;193: 471–81.

  4. 4.

    Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000;164: 4878–82.

  5. 5.

    Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583–8.

  6. 6.

    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993; 53: 851–6.

  7. 7.

    Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 2004; 126: 989–96.

Download references

Author information

Correspondence to Hiroaki Ito.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ito, H. Treatment of Crohn’s disease with anti-IL-6 receptor antibody. J Gastroenterol 40, 32–34 (2005). https://doi.org/10.1007/BF02990576

Download citation

Key words

  • IL-6
  • IL-6 receptor
  • antibody
  • therapy
  • Crohn’s disease